Meyd-873 - _best_

MEYD-873 is a targeted incident involving a coordinated intrusion into a mid-size enterprise’s cloud environment that exposed critical telemetry and allowed lateral movement. The operation combined custom tooling with opportunistic use of known misconfigurations, and its indicators suggest a financially motivated actor with moderate operational security.

By , MEYD‑873 creates a “dual‑lock” that is far more difficult for the tumor to bypass. MEYD-873

| Property | Details | |----------|---------| | | Heterocyclic pyrrolopyrimidine scaffold (C24H21N5O2) | | Molecular weight | ≈ 421 Da | | Mode of delivery | Oral tablets (Phase I formulation) | | Target | MYD1/2 adaptor proteins (key downstream effectors of Toll‑like receptor (TLR) and IL‑1R signaling) | | Intended indications | Hematologic malignancies (e.g., acute myeloid leukemia), solid tumors with MYD‑driven inflammation, select autoimmune diseases (e.g., rheumatoid arthritis) | | Development partner | Meyda Therapeutics , a spin‑out from the University of Cambridge’s Department of Chemical Biology, in collaboration with Novartis Oncology | MEYD-873 is a targeted incident involving a coordinated